Open AccessVisual outcomes, safety profile and morphometric response of optical coherence tomography biomarkers to ranibizumab biosimilar treatment in neovascular age-related macular degeneration: Real-world evidence
Author(s) -
Aditya Kelkar,
Jai Kelkar,
Mounika Bolisetty,
Shreekant B Kelkar
Publication year - 2021
Publication title -
indian journal of ophthalmology/indian journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 51
eISSN - 1998-3689
pISSN - 0301-4738
DOI - 10.4103/ijo.ijo_2977_20
Subject(s) - macular degeneration , ranibizumab , medicine , ophthalmology , visual acuity , fluorescein angiography , surgery , bevacizumab , chemotherapy
The aim of this study was to evaluate the safety, efficacy, and morphological response of intravitreal ranibizumab biosimilar (Razumab) in neovascular age-related macular degeneration (n-AMD) up to 12 weeks.